IGIrina S. Gomova

Irina S. Gomova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irina S. Gomova has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Electrolyte imbalances as predictors of atrial fibrillation recurrence following radiofrequency catheter ablation in patients with type 2 diabetes mellitus

    by Anastasia S. Myasnikova, Irina Z. Bondarenko, Olga A. Shatskaya, Igor A. Khamnagadaev, Konstantin V. Melkozerov, Raisa S. Bukatsello, Irina S. Gomova, Victor Iu. Kalashnikov, Marina V. Shestakova, Natalia G. Mokrysheva

    Aim. To evaluate the relationship between electrolyte parameters (including serum potassium, magnesium, sodium, and calcium levels), instrumental data (echocardiography), received therapy, and the frequency of early and late recurrences of atrial fibrillation in patients with type 2 diabetes mellitus after radiofrequency ablation. To determine the prognostic value of electrolyte imbalances and glycemic control as potential modifiable risk factors for the failure of interventional treatment. Materials and methods. A retrospective analysis of medical histories of patients who were hospitalized in the cardiology department of Endocrinology Research Centre from 1st January 2017 to 30th October 2025 was conducted. Results. No statistically significant differences between the groups were found in the levels of potassium, sodium, chlorides, and magnesium. The mean total calcium level in both groups was 2.4 mmol/L (p=0.032), with a larger standard deviation observed in the recurrence group. The use of sodium-glucose cotransporter-2 inhibitors was associated with a higher remission rate (67% vs 23%; p=0.005). Glycated hemoglobin (HbA1c) levels were comparable (6.6 and 7.3% respectively). Conclusion. Routinely measured electrolyte disturbances within the range typical for most patients are not independent predictors of long-term recurrences of atrial fibrillation after radiofrequency catheter ablation. Well-controlled type 2 diabetes mellitus (glycated hemoglobin 7%) and therapy with sodium-glucose cotransporter-2 inhibitors are associated with a reduced recurrence rate. Prospective studies are needed to clarify the role of calcium and dynamic electrolyte monitoring.

  • Open Access

    Clinical and epidemiological aspects of atrial fibrillation and/or atrial flutter in patients with diabetes mellitus: a cross-sectional retrospective population-based study

    by Anastasia S. Myasnikova, Irina Z. Bondarenko, Olga A. Shatskaya, Igor A. Khamnagadaev, Leonid A. Belousov, Konstantin V. Melkozerov, Irina A. Bulavina, Nikolai I. Tiurin, Raisa S. Bukatsello, Irina S. Gomova, et al.

    BACKGROUND: Diabetes mellitus (DM), atrial fibrillation (AF), and atrial flutter (AFL) are among the most prevalent cardiovascular disorders, with their incidence steadily increasing worldwide. The coexistence of DM with AF or AFL is associated with a more severe disease course and a less favorable prognosis compared with each condition occurring independently. AIM: To analyze current clinical and epidemiological aspects of atrial fibrillation (AF) and atrial flutter (AFL) in patients with diabetes mellitus, including sex- and age-related characteristics, distribution by subtype, and the relationship between diabetes mellitus and outcomes after radiofrequency catheter ablation. METHODS: A retrospective analysis of medical records was performed for patients hospitalized in the cardiology department of the National Medical Research Center for Endocrinology named after Academician I.I. Dedov (Moscow, Russia) between January 1, 2017, and October 30, 2025. RESULTS: Among the analyzed discharge summaries, 218 patients (24.9%) had type 2 diabetes mellitus. Of these patients, 30.7% had paroxysmal AF, 22.5% persistent AF, 15.1% persistent AF combined with AFL, 12.8% persistent AFL, 12.4% paroxysmal AF combined with AFL, and 6.5% paroxysmal AFL. Comparative analysis of patient groups with and without diabetes mellitus did not demonstrate convincing evidence of an effect of impaired carbohydrate metabolism on the outcomes of radiofrequency catheter ablation. CONCLUSION: This study clearly demonstrates the prevalence of diabetes mellitus among patients with AF and AFL and identifies criteria for further investigation of the impact of diabetes mellitus on the outcomes and progression of AF. Further study of this issue is required.

  • Open Access

    Severe myocardial hypertrophy and fibrosis in a patient with acromegaly: is the prevention of sudden cardiac death needed?

    by A. A. Almaskhanova, K. V. Melkozerov, E. G. Przhiyalkovskaya, N. V. Tarbaeva, R. S. Kosharnaia, I. S. Gomova, P. A. Alferova, L. Ya. Rozhinskaya, V. Y. Kalashnikov, Zh. E. Belaya, et al.

    The most common causes of death in acromegaly are cardiovascular diseases (about 60%). Heart arrhythmias and conduction disorders lead to sudden cardiac death (SCD). In this article, we described a clinical case about preventing SCD in a patient with acromegaly. We identified in this patient predictors of SCD: severe left ventricular hypertrophy, the signs of myocardial fibrosis, decreased systolic function of the left ventricular myocardium, ventricular rhythm disturbances, and heart failure. Patients with acromegaly have higher risk of heart arrhythmias due to development acromegalic cardiomyopathy with includes: left ventricular hypertrophy, diastolic and systolic dysfunction, myocardial fibrosis and electrical disturbances of the myocardium. The main limitation is the lack of special clinical recommendations for the management of this group of patients. Current recommendations based on a standard algorithm and do not consider specificity of acromegalic cardiomyopathy.

  • Open Access

    НАРУШЕНИЯ РИТМА И ПРОВОДИМОСТИ СЕРДЦА У ПАЦИЕНТОВ С АКРОМЕГАЛИЕЙ: ВСТРЕЧАЕМОСТЬ, ВЛИЯНИЕ ДЛИТЕЛЬНОСТИ ЗАБОЛЕВАНИЯ, ЛЕКАРСТВЕННОЙ ТЕРАПИИ И ФИБРОЗА МИОКАРДА

    by Фгбу «Нмиц Эндокринологии» Минздрава России, К.в. Мелкозеров, Е.г. Пржиялковская, Н.в. Тарбаева, А.а. Алмасханова, М.д. Куклина, П.а. Алферова, И.с. Гомова, Л.а. Белоусов, В.ю. Калашников, et al.

  • Arrhythmias and cardiac conduction disorders in patients with acromegaly

    by Elena Przhiyalkovskaya, Konstantin Melkozerov, Alina Almaskhanova, Natalya Tarbaeva, Maria Kuklina, Polina Alferova, Irina Gomova, Leonid Belousov, Zhanna Belaya, Alexander Vorontsov, et al.

    Cardiovascular complications including arrhythmias and cardiac conduction disorders (ACCDs) are leading risk factors for high mortality rate in acromegaly. ACCDs are the main cause of sudden cardiac death in patients with acromegaly. These disorders are detected in up to 40% of patients. Different pathogenetic mechanisms contribute to the development of concentric biventricular myocardium hypertrophy which leads to electrophysiological myocardium feature changes. The goal of the study is to evaluate the prevalence of heart complications in patients with acromegaly. Materials and methods A single-center cross-sectional study, which included 461 patients (151 men and 310 women) with acromegaly, was conducted. All patients underwent a standard medical examination including hormonal blood tests, electrocardiogram, echocardiography and electrocardiogram daily monitoring. Eighteen patients with arrhythmias (11 men and 7 women) had cardiac magnetic resonance imaging (MRI) with gadolinium-based contrast. Results The prevalence of ACCDs in patients with acromegaly was 42%. The most common types of ACCDs were sinus bradycardia – 19.1% of cases and conduction disorders of bundle branch blocks – 14.5%. Men were more likely to suffer from arrhythmias and cardiac conduction disorders than women (54.2% and 37.4%, respectively, P = 0.0005). Patients with ACCDs had a longer medical history of acromegaly (average duration 10 vs 7 years, respectively, P = 0.04). Cardiac conduction disorders were commonly observed in patients who were treated with somatostatin analogs comparing to patients who didn’t undergo this therapy (50% and 38.6% respectively, P = 0.004). Pacemakers were implanted in 3 patients, and an implantable cardioverter defibrillator was used in one patient due to susteined ventricular tachycardia. Sixty one percent of patients with acromegaly and ACCDs who underwent MRI had signs of myocardial fibrosis. Conclusion ACCDs are common in patients with acromegaly, predominantly males, increasing in prevalence with a longer history of the disease or somatostatin analog therapy. Myocardial fibrosis is supposed as one of the most likely cause of ACCDs in patients with acromegaly.

  • Open Access

    Heart arrhythmias and conduction disorders in patients with acromegaly: the role of cardiac magnetic resonance imaging

    by K. V. Melkozerov, E. G. Przhiyalkovskaya, N. V. Tarbaeva, A. A. Almaskhanova, M. D. Kuklina, P. A. Alferova, I. S. Gomova, L. A. Belousov, Z. E. Belaya, A. V. Vorontsov, et al.

    Cardiovascular complications including arrhythmias and cardiac conduction disorders are one of the main reasons of high mortality rate in acromegaly, while they have not been well explored. Aim.To estimate arrhythmias frequency in acromegaly, identify risk factors leading to the development of arrhythmia and cardiac conduction disorder, to determine the role of cardiac MRI in detecting structural and functional changes. Materials and methods.A single-center prospective cohort study, which included 461 patients (151 men and 310 women) with acromegaly, was conducted. All the patients underwent a standard medical examination, including hormonal blood test, electrocardiogram, echocardiography, electrocardiogram daily monitoring. 18 patients with arrhythmias (11 men and 7 women) had cardiac MRI with gadolinium-based contrast. Results.The results of our research show high frequency of arrhythmias and cardiac conduction disorders in patients with acromegaly 42%. Most frequent kinds of arrhythmias and cardiac conduction disorders were sinus bradycardia 19.1% of the cases and conduction disorders of bundle branch blocks 14.5%. Men were more likely to suffer from arrhythmias and cardiac conduction disorders than women (54.2% and 37.4%, respectively,p=0.0005). Not acromegaly activity but duration of the disease was a main risk factor of arrhythmias and cardiac conduction disorders. Patients with arrhythmias had a long anamnesis of acromegaly (10 and 7 years, respectively, p=0.04). Meanwhile, cardiac conduction disorders were commonly observed in the patients who were treated with somatostatin analogs comparing to the patients who didnt undergo this therapy (50% and 38.6% respectively,p=0.004). We showed that 61% of patients with acromegaly and cardiac conduction disorders who underwent magnetic resonance imaging (MRI) had the signs of myocardial fibrosis. The value of the ejection fraction of the left ventricle according to MRI was higher than with echocardiography (p=0.04). Conclusion.Arrhythmias and cardiac conduction disorders are often observed in patients with acromegaly even with remission of the disease. High risk group need careful diagnostic and monitoring approaches. Cardiac MRI is the gold standard for visualization of structural and morphological changes in the heart. Use of cardiac MRI in acromegalic patients expands our understanding of arrhythmias and cardiac conduction disorders in this disease. There are no specific laboratory markers of diffuse myocardial fibrosis, and the role of myocardial fibrosis in the occurrence of cardiac arrhythmias and conduction disorders needs further studying.


  • Open Access

    Diabetes mellitus type 2 in adults

    by Иван Иванович Дедов, Марина Владимировна Шестакова, Alexander Y. Mayorov, Minara S. Shamkhalova, Olga Yu. Sukhareva, Gagik R. Galstyan, Алла Юрьевна Токмакова, Татьяна Васильевна Никонова, Елена Викторовна Суркова, Ирина Владимировна Кононенко, et al.

    Сахарный диабет 2 типа у взрослых


  • Open Access

    Diabetes mellitus type 1 in adults

    by Иван Иванович Дедов, Марина Владимировна Шестакова, Alexander Y. Mayorov, Minara S. Shamkhalova, Татьяна Васильевна Никонова, Olga Y. Sukhareva, Елена Владимировна Пекарева, Людмила Ибрагимовна Ибрагимова, Margarita S. Mikhina, Gagik R. Galstyan, et al.

    Сахарный диабет 1 типа у взрослых


  • Open Access

    Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition

    by Ivan I. Dedov, Marina V. Shestakova, Aleksandr Y. Mayorov, Olga K. Vikulova, Gagik R. Galstyan, Tamara L. Kuraeva, Valentina A. Peterkova, Olga M. Smirnova, Elena G. Starostina, Elena V. Surkova, et al.

    Dear Colleagues! We are glad to present the 9th Edition (revised) of Standards of Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation. The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), American Diabetes Association (ADA, 2018, 2019), American Association of Clinical Endocrinologists (AACE, 2019), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2014, 2018) and Russian Association of Endocrinologists (RAE, 2011, 2012, 2015). Current edition of the Standards also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals. Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 463 million patients by the end of 2019. According to the current estimation by the International Diabetes Federation, 578 million patients will be suffering from diabetes mellitus by by 2030 and 700 million by 2045. Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 584 575 patients with DM in this country by the end of 2018 (3,1% of population) with 92% (4 238 503) Type 2 DM, 6% (256 202) Type 1 DM and 2% (89 870) other types of DM, including 8 006 women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) con- firmed that only 54% of Type 2 DM are diagnosed. So real number of patients with DM in Russia is 9 million patients (about 6% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they dont receive any treatment ant have high risk of vascular complications. Severe consequences of the global pandemics of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral, coronary and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death. In сurrent edition of the Standards: New goals of glycemic control for the elderly, based on the presence of functional dependence, as well as for pregnant women, children and adolescents, are given. Added a snippet that describes the continuous glucose monitoring. Only low-density lipoprotein cholesterol level is used as a target for lipid metabolism. Proposes more stringent target levels of blood pressure. It also features updated guidelines on stratification of treatment in newly diagnosed Type 2 diabetes: the excess of the initial level of HbA1c over the target level was used as a criterion. In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages. Recommendations for psychosocial support are added. The position of metabolic surgery as a method of treatment of DM with morbid obesity is updated. Recommendations for diagnostic and treatment of hypogonadism syndrome in men with DM are added. For the first time, evidence levels of confidence and credibility levels of recommendations for diagnostic, therapeutic, rehabilitative and preventive interventions based on a systematic review of the literature are given in accordance with the recommendations of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation. This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discus- sions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians and other medical professionals involved in the treatment of DM. On behalf of the Working Group


  • Open Access

    Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition

    by Ivan I. Dedov, Marina V. Shestakova, Aleksandr Y. Mayorov, Olga K. Vikulova, Gagik R. Galstyan, Tamara L. Kuraeva, Valentina A. Peterkova, Olga M. Smirnova, Elena G. Starostina, Elena V. Surkova, et al.

    Dear Colleagues! We are glad to present the 9th Edition (revised) of Standards of Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation. The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), American Diabetes Association (ADA, 2018, 2019), American Association of Clinical Endocrinologists (AACE, 2019), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2014, 2018) and Russian Association of Endocrinologists (RAE, 2011, 2012, 2015). Current edition of the Standards also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals. Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 463 million patients by the end of 2019. According to the current estimation by the International Diabetes Federation, 578 million patients will be suffering from diabetes mellitus by by 2030 and 700 million by 2045. Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 584 575 patients with DM in this country by the end of 2018 (3,1% of population) with 92% (4 238 503) Type 2 DM, 6% (256 202) Type 1 DM and 2% (89 870) other types of DM, including 8 006 women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) con- firmed that only 54% of Type 2 DM are diagnosed. So real number of patients with DM in Russia is 9 million patients (about 6% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they dont receive any treatment ant have high risk of vascular complications. Severe consequences of the global pandemics of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral, coronary and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death. In сurrent edition of the Standards: New goals of glycemic control for the elderly, based on the presence of functional dependence, as well as for pregnant women, children and adolescents, are given. Added a snippet that describes the continuous glucose monitoring. Only low-density lipoprotein cholesterol level is used as a target for lipid metabolism. Proposes more stringent target levels of blood pressure. It also features updated guidelines on stratification of treatment in newly diagnosed Type 2 diabetes: the excess of the initial level of HbA1c over the target level was used as a criterion. In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages. Recommendations for psychosocial support are added. The position of metabolic surgery as a method of treatment of DM with morbid obesity is updated. Recommendations for diagnostic and treatment of hypogonadism syndrome in men with DM are added. For the first time, evidence levels of confidence and credibility levels of recommendations for diagnostic, therapeutic, rehabilitative and preventive interventions based on a systematic review of the literature are given in accordance with the recommendations of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation. This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discus- sions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians and other medical professionals involved in the treatment of DM. On behalf of the Working Group